JP2025500404A5 - - Google Patents

Info

Publication number
JP2025500404A5
JP2025500404A5 JP2024537875A JP2024537875A JP2025500404A5 JP 2025500404 A5 JP2025500404 A5 JP 2025500404A5 JP 2024537875 A JP2024537875 A JP 2024537875A JP 2024537875 A JP2024537875 A JP 2024537875A JP 2025500404 A5 JP2025500404 A5 JP 2025500404A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
structural formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500404A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053738 external-priority patent/WO2023122228A1/en
Publication of JP2025500404A publication Critical patent/JP2025500404A/ja
Publication of JP2025500404A5 publication Critical patent/JP2025500404A5/ja
Pending legal-status Critical Current

Links

JP2024537875A 2021-12-23 2022-12-21 新規オーリスタチン類似体およびその免疫複合体 Pending JP2025500404A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293583P 2021-12-23 2021-12-23
US63/293,583 2021-12-23
PCT/US2022/053738 WO2023122228A1 (en) 2021-12-23 2022-12-21 Novel auristatin analogs and immunoconjugates thereof

Publications (2)

Publication Number Publication Date
JP2025500404A JP2025500404A (ja) 2025-01-09
JP2025500404A5 true JP2025500404A5 (cg-RX-API-DMAC7.html) 2026-01-06

Family

ID=86903604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537875A Pending JP2025500404A (ja) 2021-12-23 2022-12-21 新規オーリスタチン類似体およびその免疫複合体

Country Status (10)

Country Link
US (1) US20250049937A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453000A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500404A (cg-RX-API-DMAC7.html)
KR (1) KR20240152826A (cg-RX-API-DMAC7.html)
CN (1) CN118829645A (cg-RX-API-DMAC7.html)
AU (1) AU2022422015A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241878A1 (cg-RX-API-DMAC7.html)
IL (1) IL313784A (cg-RX-API-DMAC7.html)
TW (1) TW202328162A (cg-RX-API-DMAC7.html)
WO (1) WO2023122228A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
US9884817B2 (en) * 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Similar Documents

Publication Publication Date Title
CN111295389B (zh) 生物活性物偶联物及其制备方法和用途
CA3044898C (en) Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
JP7402807B2 (ja) グリピカン3抗体およびそのコンジュゲート
CA1301066C (en) Anti-tumour substance and process for producing the same
JP7465347B2 (ja) 抗c-Met抗体薬物複合体
TW202010498A (zh) 喜樹鹼肽結合物
JP2025509286A5 (cg-RX-API-DMAC7.html)
US11419944B2 (en) Non-linear self-immolative linkers and conjugates thereof
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
EA010508B1 (ru) Способ прицельного воздействия на определенные популяции клеток с помощью конъюгатов из майтансиноида и агента клеточного связывания, соединенных через нерасщепляемый линкер, конъюгаты и способы получения таких конъюгатов
JP2022512830A5 (cg-RX-API-DMAC7.html)
JP2021121590A5 (cg-RX-API-DMAC7.html)
JP6321687B2 (ja) アマトキシン誘導体
JP2024037776A5 (cg-RX-API-DMAC7.html)
JP2024540402A5 (cg-RX-API-DMAC7.html)
JPH07223969A (ja) チオエーテル結合体の製造法
JP2023512227A5 (cg-RX-API-DMAC7.html)
JP2020534326A (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
RU2004128465A (ru) Ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
CN120957758A (zh) 大环化合物及其制备方法和用途
JP2023512228A5 (cg-RX-API-DMAC7.html)
CZ161288A3 (en) Immunoglobulin conjugate, process of its preparation and pharmaceutical composition containing thereof
CN108653746A (zh) 一种多载药点、高载药配基药物偶联物
WO2024235125A1 (zh) 抗体药物偶联物及其制备方法和用途
JP2022521474A5 (cg-RX-API-DMAC7.html)